Fig. 1From: Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trialsReconstructed Kaplan-Meier plots (95% CI) of overall survival; studies recruiting patients irrespective of tumour histology. Time axis is months, vertical axis is proportion aliveBack to article page